What Is Stronger Than Percocet: Potency Ranked

Several prescription opioids are stronger than Percocet, starting with hydromorphone and oxymorphone and climbing through methadone, fentanyl, and research-grade compounds like carfentanil that are thousands of times more potent. Percocet itself combines oxycodone with acetaminophen and sits in the low-to-moderate range of opioid potency, making it a common baseline that both patients and clinicians reference when discussing pain management. But “stronger” in opioid pharmacology is trickier than it sounds, because potency and pain relief are not the same thing, and individual biology can shift any drug’s effective strength by several fold.

Where Percocet Sits on the Opioid Potency Ladder

Percocet contains oxycodone, and oxycodone taken orally is roughly one and a half to two times as potent as oral morphine, the traditional yardstick for opioid strength. A crossover study in healthy volunteers compared 15 mg of oral oxycodone against 30 mg of oral morphine and found that oxycodone produced greater pain relief across multiple types of experimental pain, including skin, muscle, and internal organ stimulation.¹ That 2:1 morphine-to-oxycodone ratio is a helpful anchor for understanding the drugs ranked above it.

What makes Percocet distinctive is not raw oxycodone strength but the acetaminophen paired with it. The combination produces a synergistic effect, meaning the two drugs working together yield more pain relief than either one alone at those doses.² That synergy lets Percocet use a lower dose of oxycodone while still managing moderate-to-severe pain effectively. Adding a non-steroidal anti-inflammatory drug like ibuprofen on top of oxycodone and acetaminophen can push relief further still, with one cancer pain trial showing a significant reduction in opioid use within 24 hours of adding ibuprofen.³

Opioids Ranked Stronger Than Percocet

The list below moves from moderately stronger to overwhelmingly stronger. Every comparison is relative to oral oxycodone (the opioid inside Percocet), using the standard clinical tool known as equianalgesic dosing, which estimates how many milligrams of one opioid produce roughly the same pain relief as a given dose of another.

Hydromorphone

Hydromorphone is roughly four to five times as potent as oral morphine milligram for milligram, which makes it about two to three times stronger than the oxycodone in Percocet. A phase 3 trial in cancer patients compared extended-release hydromorphone at 8 to 32 mg daily against controlled-release oxycodone at 10 to 40 mg daily, with both arms achieving comparable pain control, confirming hydromorphone’s higher milligram-for-milligram strength.⁴ Hydromorphone is commonly prescribed when patients need a step up from oxycodone but are not candidates for fentanyl.

Oxymorphone

Despite the similar name, oxymorphone is meaningfully stronger than oxycodone. Clinical dosing studies treated 15 mg of extended-release oxymorphone as equivalent to 30 mg of controlled-release oxycodone, placing oxymorphone at about twice oxycodone’s potency.⁵ That same study also found that at equivalent pain-relieving doses, oxymorphone caused less cognitive and psychomotor impairment than oxycodone, which is a useful reminder that potency and side effects do not always march in lockstep.

Methadone

Methadone is one of the most deceptive drugs on any potency table. Its strength relative to other opioids shifts dramatically depending on the dose a patient is already taking. At lower opioid doses, the conversion ratio of oral methadone to oral morphine is around 1:4 or 1:5, making methadone modestly strong. But at higher baseline doses, methadone becomes disproportionately more potent, with one study reporting a mean oral-methadone-to-morphine-equivalent ratio of 1:4.7 overall, and an intravenous methadone ratio as high as 1:13.5.⁶ Methadone also has an unusually long and variable half-life, which means it accumulates in the body in ways that shorter-acting opioids do not. Expert panels recommend that clinicians switching a patient to methadone reduce the calculated equianalgesic dose by 75 to 90 percent to avoid accidental overdose, far more aggressive than the 25 to 50 percent safety margin used for most other opioid switches.⁷

Fentanyl

Fentanyl is roughly 50 to 100 times more potent than morphine, which puts it somewhere around 30 to 70 times stronger than the oxycodone in Percocet. It is available by prescription as patches, lozenges, and injectable formulations, and it is also the dominant illicit synthetic opioid driving overdose deaths. Even among people with high opioid tolerance, fentanyl can cause life-threatening respiratory depression. A pharmacokinetic study found that although chronic high-dose opioid users develop measurable tolerance to fentanyl-induced breathing suppression, apnea still occurred in the tolerant group, underlining that tolerance does not make fentanyl safe.⁸

Carfentanil and Nitazenes

Carfentanil, a fentanyl analog developed for veterinary use in large animals, is estimated at roughly 100 times fentanyl’s potency, or about 10,000 times that of morphine. Nitazenes, a class of benzimidazole-derived synthetic opioids, have emerged more recently and vary in potency, with some analogs rivaling or exceeding carfentanil. These substances have contributed to what researchers describe as an exponential growth in opioid deaths.⁹ Neither carfentanil nor nitazenes have any legitimate role in human pain management. They appear almost exclusively in the illicit supply, often mixed into or sold as other drugs without the user’s knowledge.

Buprenorphine, a Special Case

Buprenorphine is roughly 25 to 40 times more potent than morphine at the receptor level, but it behaves very differently from the drugs above. It is a partial agonist, meaning it activates the opioid receptor but with a ceiling effect on both pain relief and respiratory depression. Its binding affinity is so strong that it can push full agonists like oxycodone, morphine, or fentanyl off the receptor entirely, which is why clinical guidelines recommend that patients go through mild-to-moderate opioid withdrawal before starting buprenorphine.¹⁰ If a person takes buprenorphine while a full agonist is still occupying their receptors, the displacement can trigger sudden, intense withdrawal. Buprenorphine’s potency ranking is therefore somewhat academic. It is “stronger” than Percocet at binding to receptors, but its ceiling on activation means it cannot produce the same escalating high or the same depth of respiratory depression that full agonists can at increasing doses.

Why Your Genetics Can Rearrange This Ranking

Oxycodone does not do all its work in its original form. The liver enzyme CYP2D6 converts some of it into oxymorphone, the more potent metabolite discussed above. People inherit different versions of the gene coding for CYP2D6, and those variations create a wide range of enzyme activity across the population. A large clinical study of urine drug tests found a 6.9-fold difference in the ratio of oxymorphone to oxycodone between ultrarapid metabolizers and poor metabolizers. Poor metabolizers were also about five times more likely to have no detectable oxymorphone at all.¹¹

What this means in practice is that the same dose of Percocet can behave like a significantly stronger or weaker drug depending on who takes it. A postoperative study confirmed that CYP2D6 poor metabolizers consumed markedly more oxycodone to manage the same level of surgical pain compared with extensive metabolizers, with the difference reaching statistical significance by the twelfth hour after surgery.¹² So when you see a potency chart listing one opioid as “twice as strong” as another, remember that the chart describes averages. Your personal version of that chart could look quite different.

How Route of Administration Changes Effective Strength

The same opioid molecule delivered by different routes can act as if it were a completely different drug. Oral opioids must survive first-pass metabolism in the liver, which chews up a substantial fraction of the dose before it ever reaches the brain. This is why oral morphine needs much larger milligram doses than injected morphine to achieve the same effect. A study comparing oral diacetylmorphine (pharmaceutical heroin) with oral morphine found that morphine bioavailability varied dramatically, from around 23 percent in opioid-naive subjects to over 64 percent at high doses in chronic users, suggesting that the liver’s capacity to break down the drug can become saturated.¹³

This is one reason fentanyl patches and lozenges can be so potent relative to oral opioids. Transdermal and transmucosal routes bypass much of the liver’s first-pass effect, delivering more of the active drug to the brain per milligram. It also explains why the equianalgesic tables used in clinical settings often carry separate rows for oral, intravenous, and transdermal formulations of the same drug. The potency ranking of opioids is not just a list of molecules. It is a list of molecules-at-a-given-route, and switching routes without adjusting the dose can be fatal.

When Stronger Opioids Paradoxically Increase Pain

One of the less intuitive findings in opioid research is that prolonged use of potent opioids can actually amplify pain rather than relieve it. This phenomenon, called opioid-induced hyperalgesia, involves a lowering of pain thresholds and the emergence of abnormal pain sensations that are distinct from the original condition being treated.¹⁴ In animal studies, daily morphine administration produced a gradual increase in pain sensitivity alongside a declining response to morphine’s analgesic effects. Researchers found that blocking a specific signaling molecule in sensory neurons could substantially prevent both the heightened pain sensitivity and the loss of analgesic effectiveness.¹⁵

This matters for the potency discussion because a patient whose pain worsens on a moderate opioid might assume they need something stronger, when the real problem is that the current opioid is actively making their pain worse. Climbing the potency ladder in that situation can deepen the cycle rather than break it. Recognizing hyperalgesia is tricky because it looks a lot like tolerance on the surface, both involve the drug seeming to work less well over time. The distinguishing feature is that with hyperalgesia, pain actually spreads or changes character in ways that do not match the original injury or illness.

The Overdose Reversal Problem With Ultra-Potent Opioids

Naloxone, the standard reversal agent for opioid overdoses, works by displacing opioid molecules from receptors. When the opioid involved is something like heroin or a moderate-strength prescription drug, standard naloxone doses are usually effective. But as potency climbs, the math changes. A systematic review comparing naloxone response rates found that among patients who had presumably been exposed to fentanyl or other ultra-potent opioids, only about 57 percent responded to an initial naloxone dose of 0.4 mg or less, compared to roughly 80 percent of heroin overdose patients. Median cumulative naloxone doses were also substantially higher for fentanyl-related overdoses, reaching 3.4 mg after 2015 compared with 2 mg for heroin.¹⁶

The practical implication is that a single dose of over-the-counter naloxone nasal spray may not be enough to reverse an overdose involving fentanyl or its analogs. People carrying naloxone as a harm-reduction measure are increasingly advised to carry multiple doses and to call emergency services even if the first dose seems to help, because fentanyl can outlast naloxone’s relatively short duration of action. For substances further up the potency scale, like carfentanil, the challenge is even steeper.

How Doctors Switch Between Opioids Safely

When a patient needs to move from one opioid to another, whether stepping up to something stronger or switching for side-effect reasons, clinicians use a process called opioid rotation. In principle, it involves calculating the equivalent dose of the new drug using equianalgesic tables. In practice, those tables are treated as rough guides, not precise conversion tools. An expert panel concluded that the calculated equianalgesic dose should be automatically reduced by 25 to 50 percent for most switches, because individual variation and incomplete cross-tolerance between opioids mean the new drug is often more potent in a given patient than the tables predict.⁷

The selection of a starting dose for the new opioid must account for the patient’s current tolerance, their overall health, and the specific drugs involved.¹⁷ Methadone, as described earlier, demands especially cautious reductions of 75 to 90 percent. Transdermal fentanyl, by contrast, already has a built-in conservative factor in its labeling, so additional reductions may not be necessary when switching to it. The point for anyone on opioid therapy is that moving to a “stronger” medication is never a matter of simply looking up a number on a chart and taking that dose. The chart is the starting point for a clinical judgment, not the answer.

Tolerance and What It Does to the Ranking

Tolerance gradually blunts the effect of any opioid with continued use, and it develops at different rates for different effects of the drug. A person may become tolerant to the euphoria and pain relief relatively quickly while remaining dangerously sensitive to respiratory depression at higher doses. This uneven tolerance profile is one of the main reasons that climbing the potency ladder is hazardous. Even in chronic high-dose opioid users who have built substantial tolerance, fentanyl was still capable of causing apnea in controlled research settings.⁸

Tolerance also makes potency rankings somewhat personal. A patient who has been on high-dose oxycodone for months may find that a drug technically ranked only slightly higher, like hydromorphone, provides meaningful additional relief simply because their body has not yet adapted to that particular molecule’s receptor profile. Incomplete cross-tolerance, where tolerance to one opioid does not fully transfer to another, is actually one of the main clinical reasons for rotating opioids in the first place. A fresh receptor interaction can restore some analgesic effect even without jumping to a dramatically more potent substance.

Why “Stronger” Does Not Mean “Better for Pain”

Potency tells you how many milligrams of a drug it takes to produce a given effect. It says nothing about whether that drug controls a particular type of pain more effectively, produces fewer side effects, or carries a more favorable safety profile. The oxymorphone study mentioned earlier illustrates this well. At equivalent pain-relieving doses, oxymorphone caused less cognitive impairment than oxycodone, with faster reaction times and better tracking accuracy.⁵ A drug can be more potent and simultaneously less impairing, or more potent and simultaneously less effective for a specific pain type. Potency is one axis among many.

For certain kinds of pain, particularly those involving nerves or the gut, the choice of opioid matters more than its position on a potency chart. Oxycodone, for instance, showed advantages over morphine specifically in visceral and deep-tissue pain models despite its lower traditional potency ranking relative to some other opioids.¹ The assumption that moving to a higher-potency opioid will automatically mean better pain control is one of the most common and most dangerous misconceptions in pain management. Sometimes it does. Sometimes a different mechanism, a non-opioid adjunct, or a route change accomplishes more than brute pharmacological force.